Mochi Health Alternatives Compared

Key takeaways

• Seven telehealth services we have documented to the same standard cover what most Mochi patients buy, GLP-1 care and, for some, sermorelin: Henry Meds, Hims, Ivim Health, Midi Health, PepScribe, Ro and System Labs. They are listed alphabetically, not ranked.
• The main structural difference is how you pay. Mochi charges a $79 monthly membership ($49 a month prepaid for a year) plus medication priced by dose; Ivim charges $74.99 a month plus up-front medication plans; Hims $149 a month after a $39 first month; PepScribe and System Labs price per product with no membership; Henry Meds bundles everything into one payment.
• Ivim, PepScribe and System Labs name a pharmacy on their sites; Mochi does not. Mochi starts care with a live video visit, while PepScribe and Hims rely mainly on online intake reviewed by a clinician.
• FDA warning letters are on file for Hims (September 9, 2025) and Ivim (February 20, 2026); we found none for Mochi or the other five on October 10, 2026.
• For brand GLP-1s, the manufacturer cash programs need no telehealth membership.

The Mochi Health alternatives we can document to the same standard are Henry Meds, Hims, Ivim Health, Midi Health, PepScribe, Ro and System Labs, each checked on its own website on October 9 or 10, 2026, plus the brand manufacturers' cash programs for anyone who wants Zepbound or Wegovy without a telehealth membership. Our Mochi Health review explains what Mochi offers and how its pharmacies are chosen, and our Mochi Health cost breakdown shows what a plan there actually costs; this page puts the alternatives on the same criteria.

Disclosure. The Peptide Doctrine is an independent editorial project. It currently has no sponsor and runs no advertising: we accept no payment for reviews, rankings or placements, we run no affiliate links, and we do not sell or link to "research-use" peptide vendors. Content is educational and is not medical advice.

How we chose these seven

Each alternative offers at least one of Mochi's two main lines for our readers, GLP-1 prescriptions or sermorelin, to patients in more than one state. Six are documented in our directory of online peptide clinics with facts read on their own websites on October 9, 2026; Ivim Health is documented in our Ivim Health review from its pages read on October 10. We added no provider we had not verified to that standard, and we searched FDA's warning-letter database for every name on October 10, 2026. Providers are in alphabetical order; the order is not a ranking.

We left out directory providers whose menus include compounds no pharmacy may legally make (Defy Medical, Ivy Rx and RegenMD Wellness) and those whose public pages name no relevant compound or price (Hone Health publishes medication prices only to members; Ways2Well names no peptides). The directory has their details.

Side-by-side comparison

Mochi's row uses its own pages as read on October 10, 2026, Ivim's the same day, and the others October 9, 2026. Prices change; treat this as a dated snapshot.

FDA letters: Ivim (FDA, February 2026); Hims (FDA, Hims; FDA, Hers). 'None found' means no letter addressed to the company in FDA's warning-letter database on October 10, 2026 (FDA database).

How each differs from Mochi

Henry Meds is the closest match for the breadth of compounded GLP-1s, with oral and microdose options, but its single monthly payment includes the visit, so there is no separate membership line. It does not name its pharmacy and does not publish prices outside checkout, where Mochi publishes a dose-by-dose table, and its FAQ says you may owe the balance if you leave a multi-month plan early without a medical reason.

Hims is a brand-first alternative with a lineup of approved GLP-1s similar to Mochi's brand menu. Its membership costs nearly twice Mochi's month-to-month rate after the first month, and it carries two FDA letters from September 2025 over compounded semaglutide marketing. It has announced sermorelin, glutathione and NAD+ for the end of 2026 (The Peptide Catalog, August 2026); none was on sale when we checked.

Ivim Health is the closest structural match: a membership, compounded and brand GLP-1s, and prior-authorization help. It names six compounding pharmacies where Mochi names none, but sells compounded GLP-1s on up-front plans of up to six months that cannot be cancelled mid-term, where Mochi bills medication monthly. FDA sent it a warning letter in February 2026 over how compounded products were labeled on its website. Its sermorelin is a sublingual tablet rather than Mochi's injection.

Midi Health suits women whose first concern is perimenopause or menopause. Like Mochi's insured plan, it bills visits to insurance, and it sells injectable sermorelin from $179 a month alongside GLP-1 care, from an unnamed compounding pharmacy.

PepScribe names its 503A pharmacy, publishes per-compound prices with no membership fee, and offers both compounded GLP-1s and injectable sermorelin. Its intake is asynchronous outside the nine jurisdictions that require a live visit, where Mochi starts every patient with a live video visit, and it does not require labs for peptide plans. Its GHK-Cu cream relies on FDA's interim policy for non-injectable GHK-Cu (see our GHK-Cu profile).

Ro is the option for someone who wants a brand GLP-1 and help getting it covered: its weight-loss program leads with FDA-approved drugs and an insurance concierge. It lists no sermorelin or other peptides, and its prices, pharmacy and state list were not on the pages we loaded.

System Labs is an alternative only for sermorelin: it sells an oral dissolving tablet and injections, with first-month discounts and per-product cash pricing, names The Pharmacy Hub in Miami in its FAQ, and lists no GLP-1s. No published human study has tested oral sermorelin; our sermorelin profile covers the injected doses that were studied.

Brand GLP-1s without a telehealth membership

If what you want from Mochi is a brand GLP-1, the manufacturers sell directly to cash-paying patients with a prescription from any licensed clinician, including your own doctor.

• LillyDirect (Eli Lilly): Zepbound vials or KwikPens at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg, when refills are on time; insurance cannot be combined with these prices (LillyDirect terms).
• NovoCare Pharmacy (Novo Nordisk): Wegovy at $349 a month for cash patients since November 2025 (Managed Healthcare Executive 2025); our cost guide also lists a lower introductory price for new patients in 2026 and the Wegovy pill from $149 to $299 a month.
• TrumpRx: a federal website, not a manufacturer program, that lists brand GLP-1s at the same or lower cash prices, Zepbound at an average of $346 (White House 2025). It does not write prescriptions.

The self-pay programs exclude people with Medicare, Medicaid, TRICARE or VA coverage; our tirzepatide cost guide covers the Medicare GLP-1 Bridge and insurance routes. What you give up is the program around the drug: visits, dietitians and someone to message, which is what Mochi's membership sells. Whichever route you take, check the dose and concentration on each new prescription with the peptide calculator.

Questions to ask whichever you choose

1. What is the total for the first three months and for a year, including any membership, at the dose I am likely to reach?
2. Which pharmacy fills it, in which state, and is it a 503A pharmacy or a 503B outsourcing facility?
3. If it is a compounded GLP-1, what patient-specific reason will the prescriber document, and is anything added to the formula? Our legal explainer explains why both matter.
4. What labs will be ordered, and for sermorelin, will IGF-1 be measured?
5. Can I cancel mid-plan, and what is refunded if I do?

Frequently asked questions

+−What is the best online tirzepatide program?

We do not rank, because the right choice depends on whether you want the brand drug or a compounded one, insurance or cash, and a membership or not. Among the services compared here, Mochi, Ivim, Henry Meds and PepScribe list compounded tirzepatide, Hims lists Zepbound and Mounjaro, and Ro focuses on brand GLP-1s with insurance help. Without any telehealth membership, Zepbound costs $299 to $449 a month by dose through Lilly's self-pay program with a prescription from your own clinician.

+−What is the cheapest compounded tirzepatide online?

Of the published prices we verified, Mochi's lowest dose tier was $90 a month plus a $79 membership ($49 a month if prepaid for a year), rising to $199 at its top tier, and Ivim advertised $133 a month on a six-month plan plus a $74.99 membership. Since the shortage ended, compounded tirzepatide is lawful only for a documented individual clinical need, and price is not one; Zepbound through Lilly's self-pay program starts at $299.

+−What is the best online semaglutide program?

There is no single best one. For the brand drug, Wegovy costs $349 a month through NovoCare without a telehealth membership, and Hims and Ro both prescribe brand GLP-1s, Ro with an insurance concierge. Compounded semaglutide is listed by Mochi ($60 to $99 a month by dose plus membership), Ivim, Henry Meds and PepScribe, legally limited to patients with a documented need the brand cannot meet.

+−Can telehealth prescribe peptides?

Yes, for peptides a licensed pharmacy may legally compound or a manufacturer makes, such as sermorelin, brand tesamorelin (Egrifta), bremelanotide and, within limits, semaglutide and tirzepatide, by a clinician licensed in the state you are in. No telehealth provider can legally prescribe BPC-157, TB-500 or other peptides that no pharmacy may compound.

+−What is the most trustworthy peptide company?

We do not rank on trust. The checkable signals are a pharmacy named on the website and the label, labs where the drug calls for them, a menu limited to legally compoundable drugs, published prices for the second month and beyond, and no recent FDA warning letters, which you can search in FDA's database. The tables on this page show each signal for each provider.

+−Are compounded GLP-1s going away?

The mass-market version is shrinking. FDA sent 55 warning letters to telehealth companies over compounded GLP-1 marketing in 2026 and proposed in May 2026 to keep semaglutide, tirzepatide and liraglutide off the list outsourcing facilities may use. Compounding by a 503A pharmacy for one patient with a documented clinical reason is written into the law and is not going away.

+−Where can I buy tirzepatide?

Only with a prescription. Zepbound and Mounjaro are dispensed by retail pharmacies, Zepbound is sold for cash through Lilly's self-pay program and listed on the federal TrumpRx site, and a telehealth provider such as those compared here can write the prescription. Vials sold online for 'research use' are unapproved drugs, and FDA warned sellers of them in 2026.

Sources

1. RegulatoryFDA. Warning letters database, searched October 10, 2026 for Mochi, Henry Meds, Midi Health, PepScribe, System Labs, Roman Health Ventures and ro.co: no letters addressed to them; Hims and Ivim letters listed below. (2026)
2. RegulatoryFDA. Warning letter to Ivim Services LLC dba Ivim, MARCS-CMS 721816 (compounded semaglutide and tirzepatide labeled with the Ivim name on its website). February 20, 2026; posted March 3, 2026. (2026)
3. RegulatoryFDA. Warning letter to Hims & Hers Health, Inc. dba Hims (compounded semaglutide marketing). September 9, 2025. (2025)
4. RegulatoryFDA. Warning letter to Hims & Hers Health, Inc. dba Hers (compounded semaglutide marketing). September 9, 2025. (2025)
5. NewsThe Peptide Catalog. Hims & Hers peptide launch: sermorelin, glutathione and NAD+ by end of 2026, BPC-157 pending FDA rulemaking (report on the August 10, 2026 earnings call). August 20, 2026. (2026)
6. SourcePrescriberPoint. LillyDirect Zepbound self-pay terms: $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with refills within 45 days; vials and KwikPens, as of February 2026. (2026)
7. NewsManaged Healthcare Executive. Novo Nordisk lowers Wegovy price for cash-paying patients (to $349 per month). November 2025. (2025)
8. RegulatoryThe White House. Fact sheet: most-favored-nation pricing agreements with Novo Nordisk and Eli Lilly (Zepbound from $1,086 to an average of $346 on TrumpRx; Medicare terms). November 6, 2025. (2025)